Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma depends on MMP9
Gespeichert in:
| Veröffentlicht in: | Neuro-oncology (Charlottesville, Va.) Va.), 2019-12, Vol.21 (12), p.1607-1609 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1609 |
|---|---|
| container_issue | 12 |
| container_start_page | 1607 |
| container_title | Neuro-oncology (Charlottesville, Va.) |
| container_volume | 21 |
| creator | Wirsching, Hans-Georg Arora, Sonali Zhang, Huajia Szulzewsky, Frank Cimino, Patrick J Quéva, Christophe Houghton, A McGarry Glorioso, Joseph C Weller, Michael Holland, Eric C |
| description | |
| doi_str_mv | 10.1093/neuonc/noz145 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6917394</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2273756797</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-387c482e5dc385697d2f4bf2cd232cdca9111833f308f305211110efde67222b3</originalsourceid><addsrcrecordid>eNpVUU1v3CAQRVWjfB97rTj24qwHjLEvlapNsomUqD20uSIMeJfKBhfYRE7_fEg2jdLDzIDmzXszegh9gvIMypYunNl6pxbOP0LFPqBDYIQWrKnrjy9vUjQM-AE6ivF3WRJgNeyjAwoVEAB-iP4uvZ9MkMl6h32PM5cf5mQVvrfBp01uTTN-sGmD7y5Wl0WWS0EO9tG6NZYu2c7rGadgZBqNS9g6fH1-lQcGnebJ4PVgfTfImPwosTaTcTpmEXx7-6M9QXu9HKI5fa3H6Nflxc_lVXHzfXW9_HZTKNrwVOSkqoYYpvOf1S3XpK-6nihNaE5KtgDQUNrTssnB8mEApem1qTkhpKPH6OuOd9p2o9Eq75lPEFOwowyz8NKK_zvObsTa34u6BU7bKhN8eSUI_s_WxCRGG5UZBumM30ZBCKec1bzlGVrsoCr4GIPp32SgFM-GiZ1hYmdYxn9-v9sb-p9D9AkgC5bV</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2273756797</pqid></control><display><type>article</type><title>Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma depends on MMP9</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>PubMed Central</source><creator>Wirsching, Hans-Georg ; Arora, Sonali ; Zhang, Huajia ; Szulzewsky, Frank ; Cimino, Patrick J ; Quéva, Christophe ; Houghton, A McGarry ; Glorioso, Joseph C ; Weller, Michael ; Holland, Eric C</creator><creatorcontrib>Wirsching, Hans-Georg ; Arora, Sonali ; Zhang, Huajia ; Szulzewsky, Frank ; Cimino, Patrick J ; Quéva, Christophe ; Houghton, A McGarry ; Glorioso, Joseph C ; Weller, Michael ; Holland, Eric C</creatorcontrib><identifier>ISSN: 1522-8517</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/noz145</identifier><identifier>PMID: 31412117</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Animals ; Antibodies, Neutralizing - pharmacology ; Brain Neoplasms - genetics ; Brain Neoplasms - metabolism ; Brain Neoplasms - pathology ; Brain Neoplasms - therapy ; Combined Modality Therapy ; Glioblastoma - genetics ; Glioblastoma - metabolism ; Glioblastoma - pathology ; Glioblastoma - therapy ; Humans ; Isocitrate Dehydrogenase - genetics ; Letters to the Editor ; Matrix Metalloproteinase 9 - metabolism ; Mice ; Mutation ; Oncolytic Virotherapy - mortality ; Survival Rate ; Tumor Cells, Cultured ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Vascular Endothelial Growth Factor A - immunology ; Xenograft Model Antitumor Assays</subject><ispartof>Neuro-oncology (Charlottesville, Va.), 2019-12, Vol.21 (12), p.1607-1609</ispartof><rights>The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-387c482e5dc385697d2f4bf2cd232cdca9111833f308f305211110efde67222b3</citedby><cites>FETCH-LOGICAL-c387t-387c482e5dc385697d2f4bf2cd232cdca9111833f308f305211110efde67222b3</cites><orcidid>0000-0001-6254-4204 ; 0000-0003-0441-4502 ; 0000-0002-1748-174X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917394/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917394/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31412117$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wirsching, Hans-Georg</creatorcontrib><creatorcontrib>Arora, Sonali</creatorcontrib><creatorcontrib>Zhang, Huajia</creatorcontrib><creatorcontrib>Szulzewsky, Frank</creatorcontrib><creatorcontrib>Cimino, Patrick J</creatorcontrib><creatorcontrib>Quéva, Christophe</creatorcontrib><creatorcontrib>Houghton, A McGarry</creatorcontrib><creatorcontrib>Glorioso, Joseph C</creatorcontrib><creatorcontrib>Weller, Michael</creatorcontrib><creatorcontrib>Holland, Eric C</creatorcontrib><title>Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma depends on MMP9</title><title>Neuro-oncology (Charlottesville, Va.)</title><addtitle>Neuro Oncol</addtitle><subject>Animals</subject><subject>Antibodies, Neutralizing - pharmacology</subject><subject>Brain Neoplasms - genetics</subject><subject>Brain Neoplasms - metabolism</subject><subject>Brain Neoplasms - pathology</subject><subject>Brain Neoplasms - therapy</subject><subject>Combined Modality Therapy</subject><subject>Glioblastoma - genetics</subject><subject>Glioblastoma - metabolism</subject><subject>Glioblastoma - pathology</subject><subject>Glioblastoma - therapy</subject><subject>Humans</subject><subject>Isocitrate Dehydrogenase - genetics</subject><subject>Letters to the Editor</subject><subject>Matrix Metalloproteinase 9 - metabolism</subject><subject>Mice</subject><subject>Mutation</subject><subject>Oncolytic Virotherapy - mortality</subject><subject>Survival Rate</subject><subject>Tumor Cells, Cultured</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><subject>Vascular Endothelial Growth Factor A - immunology</subject><subject>Xenograft Model Antitumor Assays</subject><issn>1522-8517</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUU1v3CAQRVWjfB97rTj24qwHjLEvlapNsomUqD20uSIMeJfKBhfYRE7_fEg2jdLDzIDmzXszegh9gvIMypYunNl6pxbOP0LFPqBDYIQWrKnrjy9vUjQM-AE6ivF3WRJgNeyjAwoVEAB-iP4uvZ9MkMl6h32PM5cf5mQVvrfBp01uTTN-sGmD7y5Wl0WWS0EO9tG6NZYu2c7rGadgZBqNS9g6fH1-lQcGnebJ4PVgfTfImPwosTaTcTpmEXx7-6M9QXu9HKI5fa3H6Nflxc_lVXHzfXW9_HZTKNrwVOSkqoYYpvOf1S3XpK-6nihNaE5KtgDQUNrTssnB8mEApem1qTkhpKPH6OuOd9p2o9Eq75lPEFOwowyz8NKK_zvObsTa34u6BU7bKhN8eSUI_s_WxCRGG5UZBumM30ZBCKec1bzlGVrsoCr4GIPp32SgFM-GiZ1hYmdYxn9-v9sb-p9D9AkgC5bV</recordid><startdate>20191217</startdate><enddate>20191217</enddate><creator>Wirsching, Hans-Georg</creator><creator>Arora, Sonali</creator><creator>Zhang, Huajia</creator><creator>Szulzewsky, Frank</creator><creator>Cimino, Patrick J</creator><creator>Quéva, Christophe</creator><creator>Houghton, A McGarry</creator><creator>Glorioso, Joseph C</creator><creator>Weller, Michael</creator><creator>Holland, Eric C</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6254-4204</orcidid><orcidid>https://orcid.org/0000-0003-0441-4502</orcidid><orcidid>https://orcid.org/0000-0002-1748-174X</orcidid></search><sort><creationdate>20191217</creationdate><title>Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma depends on MMP9</title><author>Wirsching, Hans-Georg ; Arora, Sonali ; Zhang, Huajia ; Szulzewsky, Frank ; Cimino, Patrick J ; Quéva, Christophe ; Houghton, A McGarry ; Glorioso, Joseph C ; Weller, Michael ; Holland, Eric C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-387c482e5dc385697d2f4bf2cd232cdca9111833f308f305211110efde67222b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Antibodies, Neutralizing - pharmacology</topic><topic>Brain Neoplasms - genetics</topic><topic>Brain Neoplasms - metabolism</topic><topic>Brain Neoplasms - pathology</topic><topic>Brain Neoplasms - therapy</topic><topic>Combined Modality Therapy</topic><topic>Glioblastoma - genetics</topic><topic>Glioblastoma - metabolism</topic><topic>Glioblastoma - pathology</topic><topic>Glioblastoma - therapy</topic><topic>Humans</topic><topic>Isocitrate Dehydrogenase - genetics</topic><topic>Letters to the Editor</topic><topic>Matrix Metalloproteinase 9 - metabolism</topic><topic>Mice</topic><topic>Mutation</topic><topic>Oncolytic Virotherapy - mortality</topic><topic>Survival Rate</topic><topic>Tumor Cells, Cultured</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><topic>Vascular Endothelial Growth Factor A - immunology</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wirsching, Hans-Georg</creatorcontrib><creatorcontrib>Arora, Sonali</creatorcontrib><creatorcontrib>Zhang, Huajia</creatorcontrib><creatorcontrib>Szulzewsky, Frank</creatorcontrib><creatorcontrib>Cimino, Patrick J</creatorcontrib><creatorcontrib>Quéva, Christophe</creatorcontrib><creatorcontrib>Houghton, A McGarry</creatorcontrib><creatorcontrib>Glorioso, Joseph C</creatorcontrib><creatorcontrib>Weller, Michael</creatorcontrib><creatorcontrib>Holland, Eric C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wirsching, Hans-Georg</au><au>Arora, Sonali</au><au>Zhang, Huajia</au><au>Szulzewsky, Frank</au><au>Cimino, Patrick J</au><au>Quéva, Christophe</au><au>Houghton, A McGarry</au><au>Glorioso, Joseph C</au><au>Weller, Michael</au><au>Holland, Eric C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma depends on MMP9</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><addtitle>Neuro Oncol</addtitle><date>2019-12-17</date><risdate>2019</risdate><volume>21</volume><issue>12</issue><spage>1607</spage><epage>1609</epage><pages>1607-1609</pages><issn>1522-8517</issn><eissn>1523-5866</eissn><cop>England</cop><pub>Oxford University Press</pub><pmid>31412117</pmid><doi>10.1093/neuonc/noz145</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0001-6254-4204</orcidid><orcidid>https://orcid.org/0000-0003-0441-4502</orcidid><orcidid>https://orcid.org/0000-0002-1748-174X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1522-8517 |
| ispartof | Neuro-oncology (Charlottesville, Va.), 2019-12, Vol.21 (12), p.1607-1609 |
| issn | 1522-8517 1523-5866 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6917394 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); PubMed Central |
| subjects | Animals Antibodies, Neutralizing - pharmacology Brain Neoplasms - genetics Brain Neoplasms - metabolism Brain Neoplasms - pathology Brain Neoplasms - therapy Combined Modality Therapy Glioblastoma - genetics Glioblastoma - metabolism Glioblastoma - pathology Glioblastoma - therapy Humans Isocitrate Dehydrogenase - genetics Letters to the Editor Matrix Metalloproteinase 9 - metabolism Mice Mutation Oncolytic Virotherapy - mortality Survival Rate Tumor Cells, Cultured Vascular Endothelial Growth Factor A - antagonists & inhibitors Vascular Endothelial Growth Factor A - immunology Xenograft Model Antitumor Assays |
| title | Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma depends on MMP9 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T14%3A33%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cooperation%20of%20oncolytic%20virotherapy%20with%20VEGF-neutralizing%20antibody%20treatment%20in%20IDH%20wildtype%20glioblastoma%20depends%20on%20MMP9&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Wirsching,%20Hans-Georg&rft.date=2019-12-17&rft.volume=21&rft.issue=12&rft.spage=1607&rft.epage=1609&rft.pages=1607-1609&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/noz145&rft_dat=%3Cproquest_pubme%3E2273756797%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2273756797&rft_id=info:pmid/31412117&rfr_iscdi=true |